These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 36271889)

  • 1. C3-dependent effector functions of complement.
    Zarantonello A; Revel M; Grunenwald A; Roumenina LT
    Immunol Rev; 2023 Jan; 313(1):120-138. PubMed ID: 36271889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
    Vik DP; Fearon DT
    J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans.
    Halkjær L; Troldborg A; Pedersen H; Jensen L; Hansen AG; Hansen TK; Bjerre M; Østergaard JA; Thiel S
    Front Immunol; 2020; 11():774. PubMed ID: 32431705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
    Subías Hidalgo M; Yébenes H; Rodríguez-Gallego C; Martín-Ambrosio A; Domínguez M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Eur J Immunol; 2017 Mar; 47(3):504-515. PubMed ID: 28083930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation or degradation.
    Seifert PS; Roth I; Zioncheck TF
    Atherosclerosis; 1992 Apr; 93(3):209-16. PubMed ID: 1534227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The secreted Candida albicans protein Pra1 disrupts host defense by broadly targeting and blocking complement C3 and C3 activation fragments.
    Luo S; Dasari P; Reiher N; Hartmann A; Jacksch S; Wende E; Barz D; Niemiec MJ; Jacobsen I; Beyersdorf N; Hünig T; Klos A; Skerka C; Zipfel PF
    Mol Immunol; 2018 Jan; 93():266-277. PubMed ID: 28860090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC).
    Ueki T; Mizuno M; Uesu T; Kiso T; Nasu J; Inaba T; Kihara Y; Matsuoka Y; Okada H; Fujita T; Tsuji T
    Clin Exp Immunol; 1996 May; 104(2):286-92. PubMed ID: 8625522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.
    Leijh PC; van den Barselaar MT; Daha MR; van Furth R
    J Immunol; 1982 Jul; 129(1):332-7. PubMed ID: 6979568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
    Kozel TR; Pfrommer GS
    Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus regulates activation and processing of the third component of complement.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Exp Med; 1988 Sep; 168(3):949-69. PubMed ID: 2844953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism.
    Rodriguez E; Nan R; Li K; Gor J; Perkins SJ
    J Biol Chem; 2015 Jan; 290(4):2334-50. PubMed ID: 25488663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.